Phase 1 Study of BPI-460372 in Advanced Solid Tumor Patients
Status:
Not yet recruiting
Trial end date:
2026-04-17
Target enrollment:
Participant gender:
Summary
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to
evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in
solid tumor patients.